• 1. An aptamer-based keypad lock system?
  Yaqing Liu,Jiangtao Ren,Jing Li,Jiyang Liu,Erkang Wang Chem. Commun., 2012,48, 802-804
• 2. An artificial photosynthesis system comprising a covalent triazine framework as an electron relay facilitator for photochemical carbon dioxide reduction?
  Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200
• 3. An ion-gating multinanochannel system based on a copper-responsive self-cleaving DNAzyme?
  Yang Chen,Di Zhou,Zheyi Meng,Jin Zhai Chem. Commun., 2016,52, 10020-10023
• 4. An atomically efficient, highly stable and redox active Ce0.5Tb0.5Ox (3% mol.)/MgO catalyst for total oxidation of methane?
  Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003
• 5. An investigation of surface properties, local elastic modulus and interaction with simulated pulmonary surfactant of surface modified inhalable voriconazole dry powders using atomic force microscopy
  Michael Kappl,Paul M. Young,Daniela Traini,Sanyog Jain RSC Adv., 2016,6, 25789-25798

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzothiophenes 1-benzothiophenes

Introduction to 3-(1-benzothiophen-3-yl)propanoic Acid (CAS No. 26461-80-3)

3-(1-benzothiophen-3-yl)propanoic acid, identified by the Chemical Abstracts Service Number (CAS No.) 26461-80-3, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical and chemical research. This compound belongs to the class of benzoic acid derivatives, characterized by its benzothiophene moiety linked to a propanoic acid side chain. The unique structural configuration of this molecule makes it a valuable scaffold for the development of novel therapeutic agents, particularly in the realm of medicinal chemistry.

The benzothiophene ring system is a prominent feature in many biologically active molecules, known for its ability to interact with various biological targets due to its aromatic and heterocyclic properties. In the case of 3-(1-benzothiophen-3-yl)propanoic acid, the presence of the propanoic acid group introduces additional functional diversity, enabling modifications that can fine-tune its pharmacological profile. This dual structural motif has been exploited in recent years to design compounds with enhanced binding affinity and selectivity towards specific biological receptors.

Recent advancements in computational chemistry and structure-based drug design have facilitated the exploration of 3-(1-benzothiophen-3-yl)propanoic acid as a potential lead compound for addressing various therapeutic challenges. Studies have demonstrated that derivatives of this compound exhibit promising activities in inhibiting key enzymes and receptors involved in inflammatory responses, neurodegenerative diseases, and cancer progression. The benzothiophene moiety, in particular, has been shown to modulate the activity of enzymes such as cyclooxygenase (COX) and lipoxygenase (LOX), which are pivotal in mediating inflammatory processes.

The propanoic acid side chain further contributes to the pharmacological versatility of this compound by allowing for diverse chemical modifications. For instance, esterification or amide formation at the carboxyl terminus can alter the solubility and metabolic stability of the molecule, making it more suitable for oral administration or targeted delivery systems. Additionally, introducing substituents at the aromatic positions of the benzothiophene ring can fine-tune electronic properties, thereby influencing binding interactions with biological targets.

In vitro studies have highlighted the potential of 3-(1-benzothiophen-3-yl)propanoic acid as an anti-inflammatory agent. Researchers have observed significant reductions in pro-inflammatory cytokine production when treating cellular models with this compound or its derivatives. The mechanism of action appears to involve suppression of nuclear factor kappa B (NF-κB) signaling pathways, which are central to the transcriptional regulation of inflammatory genes. These findings align with emerging evidence suggesting that modulating NF-κB activity can mitigate chronic inflammatory conditions such as rheumatoid arthritis and atherosclerosis.

Beyond its anti-inflammatory properties, 3-(1-benzothiophen-3-yl)propanoic acid has shown promise in preclinical models of cancer. Preclinical studies indicate that certain derivatives exhibit inhibitory effects on kinases and other signaling proteins involved in tumor growth and metastasis. The benzothiophene scaffold is particularly noteworthy for its ability to engage with ATP-binding pockets in enzymes like tyrosine kinases, which are often overexpressed in cancer cells. By occupying these binding sites, 3-(1-benzothiophen-3-yl)propanoic acid derivatives can disrupt downstream signaling cascades that promote cell proliferation and survival.

The synthesis of 3-(1-benzothiophen-3-yl)propanoic acid involves multi-step organic reactions that require precise control over reaction conditions and reagent selection. Common synthetic routes include cross-coupling reactions between bromobenzothiophene derivatives and propargyl halides or Grignard reagents, followed by hydrolysis to yield the carboxylic acid functionality. Advances in synthetic methodologies have enabled more efficient and scalable production processes, making it feasible to explore this compound further in clinical development.

The pharmacokinetic profile of 3-(1-benzothiophen-3-yl)propanoic acid is another critical aspect that has been extensively studied. Initial pharmacokinetic assessments suggest moderate oral bioavailability coupled with reasonable tissue distribution. However, factors such as metabolic stability and gastrointestinal absorption must be carefully optimized to enhance therapeutic efficacy. Computational modeling techniques have been employed to predict metabolic pathways and identify potential sites of degradation, aiding in the design of more robust analogs with improved pharmacokinetic properties.

Future directions in research on 3-(1-benzothiophen-3-yl)propanoic acid include exploring its potential as a prodrug or scaffold for structure-based drug design collaborations. By leveraging high-throughput screening technologies and machine learning algorithms, researchers aim to identify novel derivatives with enhanced target engagement and reduced off-target effects. Additionally, investigating its role in combination therapies may uncover synergistic effects when paired with existing treatments for complex diseases such as cancer or neurodegenerative disorders.

The growing body of evidence supporting the therapeutic potential of 3-(1-benzothiophen-3-yl)propanoic acid underscores its significance as a chemical entity within medicinal chemistry. As research progresses, this compound is poised to contribute valuable insights into drug discovery efforts aimed at addressing unmet medical needs. The integration of interdisciplinary approaches—combining synthetic chemistry, computational modeling, and biological evaluation—will be essential in unlocking its full therapeutic potential.

• 1310427-92-9(4-(5-Phenylbenzo[b]thiophen-3-yl)butanoic acid)
• 180304-00-1(Benzo[b]thiophene-3-acetic acid, 5-ethyl-)
• 83821-45-8(BENZO[B]THIOPHENE-3-ACETIC ACID, 6-METHYL-)
• 128995-45-9
• 69965-83-9(3-Dibenzothiophenepropanoic acid)
• 63471-83-0(4-(1-Benzothiophen-3-yl)-4-oxobutanoic acid)
• 24444-97-1(4-(1-benzothiophen-3-yl)butanoic Acid)
• 1606-17-3(Benzo[b]thiophene-3-acetic acid, 7-methyl-)
• 1131-09-5(Benzobthiophene-3-acetic Acid)
• 1735-12-2(2-(5-methyl-1-benzothiophen-3-yl)acetic acid)